Pulsatile drug release

Patent metadata

Field	Value
Publication number	US-9474719-B2
Application number	US-201113582913-A
Country	US
Kind code	B2
Filing date	Mar 4, 2011
Priority date	Mar 5, 2010
Publication date	Oct 25, 2016
Grant date	Oct 25, 2016

Abstract

In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a pulse at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released while a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a pulsed release of drug.

First claim

The invention claimed is:

1. A press-coated tablet formulation for a delayed, followed by a pulsed release of an active agent, the tablet comprising:
(a) a core comprising the active agent(s) together with an excipient(s); and
(b) a delayed release layer surrounding the core and consisting essentially of granules having a size of from 500 μm to 1 mm as measured by sieves;
said granules comprising a wax and particles of a low-substituted hydroxypropyl cellulose (L-HPC) in a ratio of 40:60 to 60:40 w/w;
wherein the delayed release layer substantially delays release of the active agent within the core for between 3-8 hours after administration of the tablet to a subject and thereafter a pulsed release of the active agent from the core occurs, such that at least 70% of the active agent in the core is released within 5-80 minutes;
wherein the L-HPC has a mean particle size of 55 μm, a hydroxypropyl content of 11%, and a molecular weight of 130,000, or a mean particle size of 20 μm, a hydroxypropyl content of 8%, and a molecular weight of 115,000.

2. The press-coated tablet according to claim 1 further comprising an amount of an active agent, which is the same or different to the active agent in the core, in the delayed release layer.

3. The press-coated tablet according to claim 1 wherein the active agent is designed to treat sleep maintenance insomnia.

4. The press-coated tablet according to claim 3 wherein the active agent is a sedative or hypnotic selected from the group consisting of zolpidem, Zaleplon and Zopiclone.

5. A method of treating sleep maintenance insomnia, the method comprising administering a press-coated tablet according to claim 3 comprising a sleep inducing agent to a subject immediately before the subject intends sleeping.

6. The method according to claim 5 wherein the sleep inducing agent is selected from the group consisting of zolpidem, Zaleplon and Zopiclone.

7. The method according to claim 5 wherein delayed release of the sleep inducing agent is achieved by providing a press-coated tablet comprising a delayed release layer surrounding a core comprising the sleep inducing agent.

8. The method according to claim 7 wherein the delayed release layer comprises a wax and a low-substituted hydroxypropyl cellulose (L-HPC), wherein the L-HPC has a mean particle size of 20 μm, a hydroxypropyl content of 8%, and a molecular weight of 115,000.

9. The method according to claim 7 wherein the delayed release layer comprises a wax and a low-substituted hydroxypropyl cellulose (L-HPC), wherein the L-HPC has a mean particle size of 55 μm, a hydroxypropyl content of 11%, and a molecular weight of 130,000.

10. The press-coated tablet according to claim 1 wherein the L-HPC has a mean particle size of 55 μm, a hydroxypropyl content of 11%, and a molecular weight of 130,000.

11. The press-coated tablet according to claim 1 wherein the wax is selected from the group consisting of beeswax, carnuba wax, microcrystalline wax, a hydrogenated castor oil, and a glyceryl ester.

12. The press-coated tablet according to claim 11 wherein the glyceryl ester is glycerol behenate.

13. The press-coated tablet according to claim 1 wherein the wax and L-HPC are present in a ratio of 45:55 to 55:45 w/w.

14. The press-coated tablet according to claim 1 further comprising one or more pH dependent, pH-independent, aesthetic or functional coatings.

15. The press-coated tablet according to claim 14 wherein the coating is a gastro-resistant coating.

16. A press-coated tablet according to claim 1 , comprising a sedative or hypnotic agent for treating sleep maintenance insomnia, wherein the tablet is intended to be administered immediately prior to a subject going to sleep.

17. The press-coated tablet according to claim 16 wherein the press-coated tablet comprises a delayed release layer surrounding a core comprising the sedative or hypnotic agent.

18. The press-coated tablet according to claim 1 , comprising one or more of the following active agents:
Antacids selected from the group consisting of aluminum hydroxide, magnesium carbonate, magnesium trisilicate, hydrotalcite, and simeticonealginates;
Antispasmodics selected from the group consisting of atropine sulphate, dicycloverine hydrochloride, hyoscine butylbromine, propantheline bromide, alverine citrate, and mebeverine hydrochloride;
Motility stimulants selected from the group consisting of metoclorpramide and domperidone;
H2-Receptor antagonists selected from the group consisting of Cimetidine, famotidinenizatidine, and ranitidine;
Antimuscarinics;
Chelates selected from the group consisting of Tripotassium dicitratbismuthate and sucralfate;
Prostaglandin analogues;
Aminosalicylates selected from the group consisting of balsazide sodium, mesalazine, olsalazine, and sulphasalazine;
Corticosteroids selected from the group consisting of beclometasone dipropionate, budenoside, hydrocortisone, and prednisolone;
Affecting immune response selected from the group consisting of ciclosporin, mercaptopurine, methotrexate, adalimumab, and infliximab;
Stimulant Laxatives selected from the group consisting of bisacodyl, dantron, docusate, and sodium picosulfate;
Drugs affecting biliary composition and flow;
Bile acids sequestrants selected from the group consisting of colestyramine, Oxyphencyclimine, Camylofin, Mebeverine, Trimebutine, Rociverine, Dicycloverine, Dihexyverine, Difemerine, Piperidolate, Benzilone, Mepenzolate, Pipenzolate, Glycopyrronium, Oxyphenonium, Penthienate, Methantheline, Propantheline, Otilonium bromide, Tridihexethyl, Isopropamide, Hexocyclium, Poldine, Bevonium, Diphemanil, Tiemonium iodide, Prifinium bromide, Timepidium bromide, Fenpiverinium, Papaverine, Drotaverine, Moxaverine, 5-HT3 antagonists, 5-HT4 agonists, Fenpiprane, Diisopromine, Chlorbenzoxamine, Pinaverium, Fenoverine, Idanpramine, Proxazole, Alverine, Trepibutone, Isometheptene, Caroverine, Phloroglucinol, Silicones, Trimethyldiphenylpropylamine, Atropine, Hyoscyamine, Scopolamine, Butylscopolamine, Methylscopolamine, Methylatropine, Fentonium, Cimetropium bromide, and primarily dopamine antagonists;
Proton pump inhibitors selected from the group consisting of Omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole sodium;
Opioids and opioid receptor antagonists;
Analgesics selected from the group consisting of Acetaminophen, Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Ketorolac, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tolmetin, Celecoxib, Buprenorphine, Butorphanol, Codeine, Hydrocodone, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Nalbuphine, Oxycodone, Oxymorphone, Pentazocine, Propoxyphene, and Tramadol;
Sleep drugs selected from the group consisting of Nitrazepam, Flurazepam, Loprazolam, Lormetazepam, Temazepam, Zaleplon, Zolpidem, Zopiclone, Chloral Hydrate, Triclofos, Clomethiazole, Quazepam, triazolam, Estazolam, Clonazepam, Alprazolam, Eszopiclone, Rozerem, Trazodone, Amitriptyline, Doxepin, Benzodiazepine drugs, melatonin, diphenhydramine, and herbal remedies;
Cardiac glycosides selected from the group consisting of Digoxin and digitoxin;
Phosphodiesterase inhibitors selected from the group consisting of enoximone and milrinone;
Thiazides and related diuretics selected from the group consisting of bendroflumethiazide, chlortalidone, cyclopenthiazide, inapamide, metolazone, and xipamide;
Diuretics selected from the group consisting of furosemide, bume

Assignees

• Mullen Alexander
• Stevens Howard
• Eccleston Sarah
• Univ Strathclyde

Inventors

• Mullen Alexander
• Stevens Howard
• Eccleston Sarah

Classifications

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61K9/288

  Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/282) · CPC title

• A61K9/282

  Organic compounds, e.g. fats · CPC title

• A61K9/2866 Primary

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/209

  containing drug in at least two layers or in the core and in at least one outer layer · CPC title